arly hematoma expansion occurs in approximately one third of patients with intracerebral hemorrhage (ICH) and is strongly associated with poor clinical outcome.
Stroke
January 2018 (nonexpanders) in fact expand into the ventricular space. Furthermore, revising hematoma expansion definitions to include IVH expansion may improve the predictive performance of the spot sign. Our objectives were to (1) determine the proportion of patients with ICH identified as nonexpanders by a conventional parenchymal hematoma expansion definition, who actually have IVH expansion, (2) similarly determine the proportion of false-positive spot signs that actually have IVH expansion, and (3) compare the predictive performance of the spot sign using the conventional parenchymal expansion definition with that of a revised definition incorporating IVH expansion.
Methods
We analyzed patients from the multicenter PREDICT ICH spot sign study, which has been described in detail. 3 Briefly, PREDICT was a prospective multicenter observational study of patients presenting with spontaneous ICH under 6 hours, with baseline CT, CT angiogram, and follow-up imaging at 24 hours. Exclusion criteria were ICH >100 mL, known renal impairment precluding CT angiogram, premorbid mRS >3, or terminal illness. For the current study, we excluded any patients who had missing baseline or follow-up CT, missing CT angiogram, and patients who received hemostatic therapy or underwent surgical hematoma evacuation. The PREDICT protocol was approved by local institutional research ethics boards with a waiver for deferred consent. Data, analytic methods, and study materials are only available to enrolling investigators.
Based on precedent, we defined significant hematoma expansion as ≥6 mL or ≥33% parenchymal expansion. 3, 7 We proposed a revised definition for hematoma expansion incorporating IVH expansion as ≥6 mL or ≥33% parenchymal expansion or >2 mL ventricular expansion. We chose the >2-mL IVH threshold because it was previously shown to independently predict poor outcome and mortality in acute ICH. 8 We used receiver operating curve analysis and C statistics to assess the performance of this revised definition and compared it with the C statistic of the conventional 6-mL/33% parenchymal definition using the Hanley and McNeil test. Hematoma volumes were assessed in the PREDICT study using computerized planimetry.
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Results
A total of 311 patients with baseline CT, CT angiogram, 24-hour CT, and meeting study criteria were available for analysis (Table 1) ; 39 patients did not have IVH on the baseline scan but developed IVH on 24-hour CT. Of the 311 patients, 213 (68.5%) did not meet the conventional significant hematoma expansion definition of 6 mL/33%. Of these nonexpanders, 13 of 213 (6.1%) had >2 mL expansion into the ventricular space. Four of the 13 were spot positive (Figure) . Spot sign was seen in 86 of 311 (27.7%) patients, but 40 of 86 (46.5%) patients did not meet the 6-mL/33% criteria for hematoma expansion (false positives). Of these false positives, only 4 of 40 (10%) had 2-mL expansion into the ventricular space. The area under the curve for spot sign to predict 6-mL/33% ICH expansion was 0.65 (95% confidence interval, 0.58-0.72), which was no different when >2-mL IVH expansion was added to the definition (area under the curve, 0.66; 95% confidence interval, 0.58-0.72; z=0.0627; P=0.95 for comparison); positive predictive value increased marginally from 53.5% to 58.1% (Table 2 ).
Discussion
We report that a small proportion of patients with ICH classified as nonexpanders and false-positive spot signs actually expand into the ventricular space. Studies of early hematoma expansion typically limit volume measurements to the parenchymal component of ICH. Conventional definitions of hematoma expansion have relied on absolute and relative growth thresholds, which although clinically significant, 7 may underestimate the ICH expansion when there is extension into the intraventricular compartment. Although we report that this occurs in only a minority of patients (6.1% or 13 of 213 patients classified as nonexpanders using parenchymal definitions), classifying these patients as expanders may be helpful when designing treatment trials aiming to mitigate early hematoma expansion. It may also be helpful to understand situations where a treatment has an apparent clinical benefit, without appearing to reduce parenchymal hematoma expansion (eg, Interact-2 10 ). When we incorporated ventricular expansion into the definition of significant ICH expansion, 10% of spot signs initially classified as false positive were reclassified as true positive, thereby marginally increasing its positive predictive value. However, the spot sign sensitivity remained poor, and there was no improvement in its overall predictive performance. Although the spot sign was initially a highly promising predictive marker for hematoma expansion, 4,5 subsequent studies revealed considerable variability in predictive performance, in part, because of image acquisition phase, 11 tube current, 12 and onset-to-imaging time. 6 Our study suggests that accounting for ventricular expansion is insufficient to improve spot sign performance and supports the need for other predictive features on neuroimaging, such as heterogeneity and morphology. 13 Our study has important limitations. There is no clear consensus on the best definition for ventricular expansion in ICH. Nevertheless, we based our threshold for ventricular expansion on prior studies showing a relationship to clinical outcome. In addition, the boundaries between parenchyma and ventricle can be difficult to demarcate when anatomic landmarks are disrupted by large hematomas, requiring subjective interpretation by the image readers. Furthermore, although the original PREDICT study was prospective in design, this analysis was retrospective and potentially susceptible to confounding. Finally, our sample size is relatively small and warrants replication in a larger cohort.
Summary
We report that refining the definition of significant ICH expansion to account for ventricular expansion had minimal effect on the predictive performance of the spot sign. This reinforces the need to develop better predictive models for ICH expansion, perhaps by combining spot sign with clinical features and noncontrast CT markers.
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